Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Extension Study of Ataluren in Nonsense-Mutation-Mediated Cystic Fibrosis
2010-019692-30Phase 3Completed
- Sponsor
- PTC Therapeutics, Inc
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ataluren in cystic fibrosis (CF), sponsored by PTC Therapeutics, Inc. Primary endpoint: Long-term safety profile. Started May 2010; status: completed.
02
Drugs
ataluren
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2010-019692-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019692-30.